neion-bio
(2)
Dimi Kellari and the trouble with a perfectly good design
Before co-founding Neion Bio, Demetrios (Dimi) Kellari studied why aircraft designs persist and helped build systems for solar energy and autonomous roads. His career keeps returning to a practical question: when should you improve the machinery, and when should you change the design?
Dimi Kellari
Dimi Kellari is the co-founder and CEO of Neion Bio, a New York biotech using genetically engineered chicken eggs as biological factories to produce complex biologics like monoclonal antibodies at a fraction of the usual cost. An MIT-trained aerospace engineer who previously built autonomous-vehicle infrastructure at Cavnue and worked at Alphabet's X moonshot factory and McKinsey, Kellari co-founded Neion in 2024 with biologist Dr. Sam Levin around a single question: why, in 2024, are we still making our most important medicines in hamster cells? In June 2026 the company closed an oversubscribed $23 million Series A led by Caffeinated Capital.